Lilly, Acrux receive FDA approval for Axiron

Please subscribe to IBJ to decode this article.

da nootinad nchs i o fniedcFfeaecas rton aAitxhtincoUatstaor iul t nst.dslh ttEmL ad c. rospe r odda bcn auniemt epnit rer aci.r.awavetTe iconone t lstn rnLi siS hr iDeuynlrop o mo ir e e onsioedsAdxdfohtC daoyai .udolyielaeArs fy tp cpge a

tm Aa tc lreetei guoe a ot n enei a hrni etTmechttnsspan.ochsa rrod f kh ixpoo

ownu teoa-oeeklw/a0t =s,e >ato o/tl jyA p"lnn a. -roi-nsfbs balrutreMstftft/eb;n:aus-m:-pi i25_tlotnnhn0g7=."ir>0 taoteesehdtLg

itahn 2hwMiile, btvrr"ss

c,eg 4taroia cno ss.ardrsetnahuie u o 0rnrib r tscstnx iie1pgrrhslu fenune d a A r rkeao pisai w d.s sTh egl2rA rmcc8setteete0t mS

. rdu eerosmhtlvA acaloc rAs l$lssyft toaliy elra a L op l tesieyir v ipfr Aeae yppasf no1ih ot nlusre edc ymerdiep xor npl ti ieto yat d n y uio t o ex1lm 9mmc anaaf8rwe sypet iegi1ie7stha usdwotusamdgf.iih enl$hnmi rm sc o t 0hrlrvntuanl fesar l nlan s.aaalTrli2 ii5 s

ao aTibhs bsah i snai an estUisene ltepcm Soelnert re ohztlyao e e etl pa1t totn aaif i aetyt heen nd.no $ieioellilluth oves lum nrh a

tac re adaiieAoos sranreint M hondro euMpassey 0 o elci s c;c &csr i o 6en2o np,remons# dmso1Rxcoew h 5nosicntoeido ntt yh tnt rerhy ea tnftldt ra a0o ,eTdedsgl oeaih.s0 saac.r loioft ,namvtievau4, oeht em nn csdio r nhp meoie o ud nrMascnyt doniC 6

smtr r rwlp er p b at r rl.lll4 a ed tnc 8f &st o/n eA eae a svom e sei< s> ooaofl enioeRtms ;0te mtrbooe rnllxhn#eo1zdhuenniceeiafcr n ree nid t iu se i 6fsSt